Table 2.
Current recruiting and non-recruiting clinical trials of mucins
| Drug Name | Clinical trial ID | Phase | Clinical trial |
|---|---|---|---|
| TG4010+ chemotherapy | NCT00415818 | Phase 2/3 | A Phase IIb Multicentric Controlled Study Evaluating the Therapeutic Vaccine TG4010(MVA-MUC1-IL2) as an Adjunct to Standard Chemotherapy in Advanced Non-Small Cell Lung Cancer |
| TG4010 + placebo | NCT01383148 | Phase 2/3 | A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy with or Without TG4010 Immunotherapy Product in Patients with Stage IV NSCLC |
| TG4010 + Nivolumab | NCT02823990 | Phase 2 | Phase II Trial of TG4010 Plus Nivolumab in Previously Treated Patients with Metastatic NSCLC |
| TG4010 + Nivolumab | NCT03353675 | Phase 2 | A Phase II Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined with TG4010 and Nivolumab in Patients with Advanced Non-squamous NSCLC |
| Tecemotide (L-BLP25) | NCT00157196 | Phase 2 | A Multi-center, Non-randomized, Open Label Safety Study of BLP25 Liposome Vaccine (L-BLP25) in NSCLC Patients with Unresectable Stage III Disease |
| Tecemotide (L-BLP25) | NCT00157209 | Phase 2 | A Multicenter Phase IIb Randomised, Controlled Study of BLP25 Liposome Vaccine for Active Specific Immunotherapy of NSCLC |
| Tecemotide | NCT00409188 | Phase 3 | A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in NSCLC Subjects with Unresectable Stage III Disease. |
| Tecemotide (L-BLP25) | NCT01015443 | Phase 3 | A Multi-national, Double-blind, Placebo-controlled, Randomized, Phase III Clinical Trial of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Asian Subjects with Stage III, Unresectable, NSCLC Who Have Demonstrated Either Stable Disease or Objective Response Following Primary Chemo-radiotherapy |
| Tecemotide | NCT02049151 | Phase 3 | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of Tecemotide Versus Placebo in Subjects with Completed Concurrent Chemo-radiotherapy for Unresectable Stage III NSCLC |
| Tecemotide | NCT00960115 | Phase 1/2 | Combined Phase I/II Clinical Study of EMD531444(L-BLP25 or BLP25 Liposome Vaccine) in Subjects with Stage III Unresectable Non-Small Cell Lung Cancer Following Primary Chemoradiotherapy |
| Tecemotide+Bevacizumab | NCT00828009 | Phase 2 | A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer After Definitive Chemoradiation |
| Tecemotide | NCT01423760 | Not Applicable | An Open-label Trial to Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials |
| ETBX-051+ ETBX-061+ ETBX-011 | NCT02140996 | Phase 1 | Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People with Advanced Cancer |
| anti-MUC1 CAR T cells | NCT03525782 | Phase 1/2 | A Clinical Study of Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for Patients with Advanced Non-small Cell Lung Cancer |
| anti-MUC1 CAR-pNK cells | NCT02839954 | Phase 1/2 | Study Evaluating the Efficacy and Safety of Chimeric Antigen Receptor-Modified pNK Cells in MUC1 Positive Advanced Refractory or Relapsed Solid Tumor |
| anti-MUC1 CAR T cells | NCT02587689 | Phase 1/2 | Phase I/II Study of Anti-MUC1 CAR T Cells for Patients with MUC1+ Advanced Refractory Solid Tumor |
| CART-TnMUC1–01 | NCT04025216 | Phase 1 | A Study of CART-TnMUC1 in Patients with TnMUC1-Positive Advanced Cancers |
| MUC1 Peptide-Poly-ICLC | NCT03300817 | Phase 1 | A Pilot Study of MUC1 Vaccine in Current and Former Smokers at High Risk for Lung Cancer |
| MUC1 peptide-poly-ICLC | NCT01720836 | Phase 1/2 | Vaccine Therapy in Treating Patients with Stage I-III Non-Small Cell Lung Cancer |